keyword
MENU ▼
Read by QxMD icon Read
search

Anastrozole

keyword
https://www.readbyqxmd.com/read/28816986/efficacy-and-safety-of-endocrine-monotherapy-as-first-line-treatment-for-hormone-sensitive-advanced-breast-cancer-a-network-meta-analysis
#1
Jingwen Zhang, Yanhong Huang, Changyi Wang, Yuanfang He, Shukai Zheng, Kusheng Wu
BACKGROUND: Endocrine therapy was recommended as the preferred first-line treatment for hormone receptor-positive (HR+, i.e., ER+ and/or PgR+), human epidermal growth factor receptor-2-negative (HER2-) postmenopausal advanced breast cancer (ABC), but which endocrine monotherapy is optimal lacks consensus. We aimed to identify the optimal endocrine monotherapy with a network meta-analysis. METHODS: We performed a network meta-analysis for a comprehensive analysis of 6 first-line endocrine monotherapies (letrozole, anastrozole, exemestane, tamoxifen, fulvestrant 250 mg and 500 mg) for HR+ HER2- metastatic or locally advanced breast cancer in postmenopausal patients...
August 2017: Medicine (Baltimore)
https://www.readbyqxmd.com/read/28783867/absence-of-effect-of-intravaginal-miconazole-clindamycin-nonoxynol-9-and-tampons-on-the-pharmacokinetics-of-an-anastrozole-levonorgestrel-intravaginal-ring
#2
Rüdiger Nave, Stefan Klein, André Müller, Xinying Chang, Joachim Höchel
A study was performed to investigate the effect of an intravaginally administered antimycotic, an antibiotic, and a spermicide plus the co-usage of tampons on the pharmacokinetics (PK) of levonorgestrel (LNG) and anastrozole (ATZ) administered as an intravaginal ring (IVR) releasing 1050 μg ATZ per day and 40 μg LNG per day. In this parallel-group, randomized, open-label study, healthy premenopausal women received an IVR as the main treatment. Comedications were administered on 3 consecutive evenings during treatment with IVR on days 9-11 (group A, 400 mg miconazole; group B, 100 mg clindamycin; group C, 75 mg nonoxynol-9); tampon co-usage (group D) was performed on days 20-23...
August 7, 2017: Journal of Clinical Pharmacology
https://www.readbyqxmd.com/read/28775043/oestrogen-inhibition-reverses-pulmonary-arterial-hypertension-and-associated-metabolic-defects
#3
Xinping Chen, Eric D Austin, Megha Talati, Joshua P Fessel, Eric H Farber-Eger, Evan L Brittain, Anna R Hemnes, James E Loyd, James West
Increased oestrogen is a strong epidemiological risk factor for development of pulmonary arterial hypertension (PAH) in patients, associated with metabolic defects. In addition, oestrogens drive penetrance in mice carrying mutations in bone morphogenetic protein receptor type II (BMPR2), the cause of most heritable PAH. The goal of the present study was to determine whether inhibition of oestrogens was effective in the treatment of PAH in these mice.The oestrogen inhibitors fulvestrant and anastrozole were used in a prevention and treatment paradigm in BMPR2 mutant mice, and tamoxifen was used for treatment...
August 2017: European Respiratory Journal: Official Journal of the European Society for Clinical Respiratory Physiology
https://www.readbyqxmd.com/read/28768570/primary-cytoreductive-surgery-and-adjuvant-hormonal-monotherapy-in-women-with-advanced-low-grade-serous-ovarian-carcinoma-reducing-overtreatment-without-compromising-survival
#4
Amanda N Fader, Jennifer Bergstrom, Amelia Jernigan, Edward J Tanner, Kara Long Roche, Rebecca L Stone, Kimberly L Levinson, Stephanie Ricci, Stephanie Wethingon, Tian-Li Wang, Ie-Ming Shih, Bin Yang, Gloria Zhang, Deborah K Armstrong, Stephanie Gaillard, Chad Michener, Robert DeBernardo, Peter G Rose
OBJECTIVES: Women with advanced-stage, low-grade serous ovarian carcinoma (LGSC) have low chemotherapy response rates and poor overall survival. Most LGSC tumors overexpress hormone receptors, which represent a potential treatment target. Our study objective was to determine the outcomes of patients with advanced-stage LGSC treated with primary cytoreductive surgery (CRS) and hormone therapy (HT). METHODS: A retrospective study was performed at two academic cancer centers...
July 30, 2017: Gynecologic Oncology
https://www.readbyqxmd.com/read/28765859/clinical-consultations-and-investigations-before-and-after-discontinuation-of-endocrine-therapy-in-women-with-primary-breast-cancer
#5
Derrick Lopez, Anna Kemp-Casey, Christobel Saunders, Elizabeth Roughead, Frances Boyle, Max Bulsara, David Preen
OBJECTIVE: Although clinical trials recommend that women with hormone-dependent primary breast cancer remain on endocrine therapy for at least 5 years, up to 60% discontinue treatment early. We determined whether these women had consulted with clinicians or had investigations for cancer recurrence or metastasis around the time they discontinued endocrine therapy, and whether clinical contact continued after discontinuation. METHODS: We performed case-control and cohort studies of women from the 45 and Up Study who were diagnosed with invasive primary breast cancer between January 2003 and December 2008, and who had ≥12 months of anastrozole, exemestane, letrozole or tamoxifen subsequently dispensed...
July 26, 2017: Public Health Research & Practice
https://www.readbyqxmd.com/read/28755088/adjuvant-endocrine-monotherapy-for-postmenopausal-early-breast-cancer-patients-with-hormone-receptor-positive-a-systemic-review-and-network-meta-analysis
#6
REVIEW
Zhu Yu, Xiaojing Guo, Yicheng Jiang, Lei Teng, Jinwu Luo, Pengfei Wang, Yunsheng Liang, Haitian Zhang
BACKGROUND: In patients with hormone receptor-positive postmenopausal of early stage breast cancer, adjuvant endocrine monotherapies include letrozole, anastrozole, exemestane, toremifene and tamoxifen. But the optimum regimen remains controversial. METHODS: PubMed, Cochrane Database and ClinicalTrials.gov were systematically reviewed of abstract for randomized-controlled trials (RCTs) to assess the efficacy of tamoxifen, letrozole, exemestane, anastrozle and toremifene for postmenopausal patients with hormone-receptor positive (HR+), who have not received prior therapy for early stage breast cancer...
July 28, 2017: Breast Cancer: the Journal of the Japanese Breast Cancer Society
https://www.readbyqxmd.com/read/28739702/anastrozole-induced-autoimmune-hepatitis-a-rare-complication-of-breast-cancer-therapy
#7
Oleksandra Klapko, Elie Ghoulam, Shriram Jakate, Sheila Eswaran, Lydia Usha
BACKGROUND: Autoimmune hepatitis (AIH) is an extremely rare complication of anastrozole therapy. It presents with elevated liver function tests. The diagnosis is established by detecting high titers of autoantibodies such as antinuclear antibodies, anti-smooth muscle antibodies, and elevated immunoglobulins. It is confirmed with a liver biopsy showing interface rosetting and an increased number of plasma cells. Early diagnosis of anastrozole-induced AIH is important because it allows anastrozole to be discontinued and immunomodulatory treatment to be promptly initiated...
August 2017: Anticancer Research
https://www.readbyqxmd.com/read/28700478/impact-of-nonsteroidal-aromatase-inhibitors-on-steroid-profile-in-a-chinese-population
#8
RANDOMIZED CONTROLLED TRIAL
Yanyi Xing, Xin Liu, Mengmeng Yan, Tianqi Chen, Fei Lu, Bing Xu, Yan Gong, Fuhao Chu, Haimin Lei
Steroid profiling was introduced to determine the endogenous steroid misuse in sports. Thus, screening for the exogenous use of these prohibited substances can be established by monitoring a range of endogenous steroids, which constitute the steroid profile and evaluate their concentrations and ratios against reference values. The steroid profiling is currently based on population statistics. As large interindividual variations exist, athlete biological passport (ABP) analysis is ongoing. This study aimed to identify new biomarker(s) for aromatase inhibitor detection in sports using statistical analysis and adapt the model into ABP analysis...
July 2017: Medicine (Baltimore)
https://www.readbyqxmd.com/read/28680952/a-review-of-fulvestrant-in-breast-cancer
#9
REVIEW
Mark R Nathan, Peter Schmid
Fulvestrant is a selective estrogen receptor degrader that binds, blocks and degrades the estrogen receptor (ER), leading to complete inhibition of estrogen signaling through the ER. This review article further explains the mechanism of action of the drug and goes on to review the trials carried out to optimize its dosing. Multiple trials have been undertaken to compare fulvestrant with other endocrine treatments, and results have shown it to have similar efficacy to anastrozole, tamoxifen and exemestane at 250 mg every 28 days...
2017: Oncology and Therapy
https://www.readbyqxmd.com/read/28675545/cost-effectiveness-analysis-of-fulvestrant-versus-anastrozole-as-first-line-treatment-for-hormone-receptor-positive-advanced-breast-cancer
#10
H Ding, L Fang, W Xin, Y Tong, Q Zhou, P Huang
Although recent studies demonstrated that fulvestrant is superior to anastrozole as first-line treatment for hormone receptor (HR)-positive advanced breast cancer, the cost-effectiveness of fulvestrant versus anastrozole remained uncertain. Thus, the current study aimed to evaluate the cost-effectiveness of fulvestrant compared with anastrozole in the first-line setting. A Markov model consisting of three health states (stable, progressive and dead) was constructed to simulate a hypothetical cohort of patients with HR-positive advanced breast cancer...
July 3, 2017: European Journal of Cancer Care
https://www.readbyqxmd.com/read/28669712/lessons-in-precision-oncology-from-neoadjuvant-endocrine-therapy-trials-in-er-breast-cancer
#11
Matthew J Ellis
For post-menopausal women with clinical stage II/III estrogen receptor positive (ER+) breast cancer neoadjuvant endocrine therapy (NET) is an under-utilized and low-toxicity alternative to chemotherapy for increasing breast conservation rates. Individual responses to endocrine therapy can also be used to tailor systemic treatment. The Preoperative Endocrine Prognostic Index (PEPI) was developed to identify patients at low risk of relapse after NET so that adjuvant chemotherapy can safely be avoided. In a recent validation study, patients with pathological stage 1 or 2A breast cancers with a Ki67 value of 2...
June 30, 2017: Breast: Official Journal of the European Society of Mastology
https://www.readbyqxmd.com/read/28664485/-per-vaginam-topical-use-of-hormonal-drugs-in-women-with-symptomatic-deep-endometriosis-a-narrative-literature-review
#12
REVIEW
Laura Buggio, Caterina Lazzari, Ermelinda Monti, Giussy Barbara, Nicola Berlanda, Paolo Vercellini
PURPOSE: We aim to provide a comprehensive overview of the role of the vagina as a route for drug delivery and absorption, with a particular focus on the use of vaginal hormonal compounds for the treatment of deep infiltrating symptomatic endometriosis. METHODS: A MEDLINE search through PubMed was performed to identify all published studies in English language on vaginal hormonal treatments for symptomatic endometriosis. RESULTS: Main advantages of the vaginal route include avoidance of the hepatic-first pass metabolic effect, the possibility of using lower therapeutic dosages, and the reduction of side effects compared with the oral administration...
June 29, 2017: Archives of Gynecology and Obstetrics
https://www.readbyqxmd.com/read/28653929/evaluation-of-ed50-and-5%C3%AE-reductase-inhibitor-activities-of-some-thiopyrimidine-pyrane-pyrazoline-and-thiazolopyrimidine-derivatives
#13
Abd El-Galil E Amr, Mohamed A Al-Omar, Mohamed M Abdalla
In this work, twenty-one thiopyrimidine (1-21) candidates containing a pyrane, pyrazoline and thiazolopyrimidine ring screened for their ED50 and 5α-reductase inhibitors comparable to that of Anastrozole as positive drug. Some of the tested product showed moderate 5α-reductase inhibitors with lower toxicity. The detailed ED50 and 5α-reductase inhibitor activities of the synthesized compounds were studied.
May 2017: Pakistan Journal of Pharmaceutical Sciences
https://www.readbyqxmd.com/read/28651157/different-patterns-in-the-risk-of-newly-developed-fatty-liver-and-lipid-changes-with-tamoxifen-versus-aromatase-inhibitors-in-postmenopausal-women-with-early-breast-cancer-a-propensity-score-matched-cohort-study
#14
Namki Hong, Han Gyul Yoon, Da Hea Seo, Seho Park, Seung Il Kim, Joo Hyuk Sohn, Yumie Rhee
BACKGROUND: Management of metabolic complications of long-term adjuvant endocrine therapy in early breast cancer remained an unmet need. We aimed to compare the effects of tamoxifen (TMX) and aromatase inhibitors (AIs) on the risk of fatty liver in conjunction with longitudinal changes in the serum lipid parameters. METHODS: Among 1203 subjects who were taking adjuvant TMX or AI (anastrozole or letrozole) without fatty liver at baseline, those taking TMX or AI were 1:1 matched on the propensity score...
June 23, 2017: European Journal of Cancer
https://www.readbyqxmd.com/read/28643023/variable-aromatase-inhibitor-plasma-concentrations-do-not-correlate-with-circulating-estrogen-concentrations-in-post-menopausal-breast-cancer-patients
#15
Daniel L Hertz, Kelly A Speth, Kelley M Kidwell, Christina L Gersch, Zeruesenay Desta, Anna Maria Storniolo, Vered Stearns, Todd C Skaar, Daniel F Hayes, N Lynn Henry, James M Rae
PURPOSE: The aromatase inhibitors (AI) exemestane (EXE), letrozole (LET), and anastrozole suppress estrogen biosynthesis, and are effective treatments for estrogen receptor (ER)-positive breast cancer. Prior work suggests that anastrozole blood concentrations are associated with the magnitude of estrogen suppression. The objective of this study was to determine whether the magnitude of estrogen suppression, as determined by plasma estradiol (E2) concentrations, in EXE or LET treated patients is associated with plasma AI concentrations...
June 22, 2017: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/28614542/use-of-anastrozole-in-the-chemoprevention-and-treatment-of-breast-cancer-a-literature-review
#16
Maria da Conceição Barros-Oliveira, Danylo Rafhael Costa-Silva, Danielle Benigno de Andrade, Umbelina Soares Borges, Cléciton Braga Tavares, Rafael Soares Borges, Janaína de Moraes Silva, Benedito Borges da Silva
Aromatase inhibitors have emerged as an alternative endocrine therapy for the treatment of hormone sensitive breast cancer in postmenopausal women. The use of third-generation inhibitors represented by exemestane, letrozol and anastrozole is currently indicated. Anastrozole is a nonsteroidal compound and a potent selective inhibitor of the aromatase enzyme. Although a few studies have shown that its pharmacodynamic and pharmacokinetic properties may be affected by interindividual variability, this drug has been recently used in all configurations of breast cancer treatment...
April 2017: Revista da Associação Médica Brasileira
https://www.readbyqxmd.com/read/28590445/surface-modification-of-carbonate-apatite-nanoparticles-enhances-delivery-and-cytotoxicity-of-gemcitabine-and-anastrozole-in-breast-cancer-cells
#17
Fitya Syarifa Mozar, Ezharul Hoque Chowdhury
pH sensitive nanoparticles of carbonate apatite (CA) have been proven to be effective delivery vehicles for DNA, siRNAs and proteins. More recently, conventional anti-cancer drugs, such as doxorubicin, methotrexate and cyclophosphamide have been successfully incorporated into CA for intracellular delivery to breast cancer cells. However, physical and chemical properties of drug molecules appeared to affect their interactions with CA, with hydrophillic drug so far exhibiting better binding affinity and cellular uptakes compared to hydrophobic drugs...
June 7, 2017: Pharmaceutics
https://www.readbyqxmd.com/read/28578073/identification-of-endocrine-disrupting-chemicals-acting-on-human-aromatase
#18
Roberta Baravalle, Alberto Ciaramella, Francesca Baj, Giovanna Di Nardo, Gianfranco Gilardi
Human aromatase is the cytochrome P450 catalysing the conversion of androgens into estrogens playing a key role in the endocrine system. Due to this role, it is likely to be a target of the so-called endocrine disrupting chemicals, a series of compounds able to interfere with the hormone system with toxic effects. If on one side the toxicity of some compounds such as bisphenol A is well known, on the other side the toxic concentrations of such compounds as well as the effect of the many other molecules that are in contact with us in everyday life still need a deep investigation...
June 1, 2017: Biochimica et Biophysica Acta
https://www.readbyqxmd.com/read/28500839/evaluating-the-efficacy-of-post-surgery-adjuvant-therapies-used-for-ductal-carcinoma-in-situ-patients-a-network-meta-analysis
#19
Li Wang, Yaoxiong Xia, Dequan Liu, Yueqin Zeng, Li Chang, Lan Li, Yu Hou, Lv Ge, Wenhui Li, Zhijie Liu
OBJECTIVE: Post-surgery adjuvant therapies are very important for patients suffering from ductal carcinoma in situ (DCIS). In this study we conducted a network meta-analysis (NMA) to evaluate the efficacy of different post-surgery adjuvant therapies including tamoxifen, anastrozole and radiation therapy (RT) and their combinations (RT+ tamoxifen and RT+ anastrozole). METHODS: We searched several databases, including Embase, MEDLINE / PUBMED, Cochrane Library, and Science Citation Index, for relevant studies...
April 21, 2017: Oncotarget
https://www.readbyqxmd.com/read/28498256/paragon-anzgog-0903-phase-2-study-of-anastrozole-in-women-with-estrogen-or-progesterone-receptor-positive-platinum-resistant-or-refractory-recurrent-ovarian-cancer
#20
Anthony Bonaventura, Rachel L OʼConnell, Cristina Mapagu, Philip J Beale, Orla M McNally, Linda R Mileshkin, Peter T Grant, Alison M Hadley, Jeffery C H Goh, Katrin M Sjoquist, Julie Martyn, Anna DeFazio, James Scurry, Michael L Friedlander
BACKGROUND: There is some evidence that a subset of patients with recurrent ovarian cancer may benefit from antiestrogen therapy. The Paragon study is a basket protocol that includes a series of phase 2 trials investigating the activity of anastrozole in patients with estrogen or progesterone receptor-positive recurrent gynecological cancers. We report the results of treatment in patients with platinum-resistant or -refractory recurrent epithelial ovarian cancer. METHODS: Postmenopausal women who had estrogen and/or progesterone receptor-positive platinum-resistant or platinum-refractory recurrent ovarian cancer and disease measurable by Response Evaluation Criteria In Solid Tumors (RECIST) version 1...
June 2017: International Journal of Gynecological Cancer
keyword
keyword
11983
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"